Company Zeo ScientifiX, Inc.

ZEOX

US68621D2062

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Pharmaceuticals Wholesale

Market Closed - OTC Markets Other stock markets 03:59:35 2024-04-23 pm EDT			5-day change	1st Jan Change
1.4 ^USD	-4.37%		-12.50%	+37.25%

Mar. 18	Zeo ScientifiX, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
Mar. 05	Zeo ScientifiX, Inc. has Changed its Ticker to ZEOX from OCEL	CI

Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. It develops biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent and an autologous non-manipulated biologic containing the nanoparticle fraction from a patientâs own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry, administered by doctors and clinics. The Companyâs product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs. Patient Pure X, its autologous product, is a non-manipulated biologic containing the nanoparticle fraction from a patientâs own peripheral blood.

Number of employees: 23

USD in Million	2022	Weight	2023	Weight	Delta
Biological Therapeutics 100.0 %	6	100.0 %	5	100.0 %	-29.78%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	6	100.0 %	5	100.0 %	-29.78%

Managers	Title	Age	Since
Harry Leider CEO	Chief Executive Officer	66	23-06-05
Ian Bothwell DFI	Director of Finance/CFO	63	16-11-03
Howard Golub CTO	Chief Tech/Sci/R&D Officer	71	23-06-05
Jacqueline Domenech COO	Chief Operating Officer	-	22-09-19
David Aciego CTO	Chief Tech/Sci/R&D Officer	-	22-09-19
George Shapiro CTO	Chief Tech/Sci/R&D Officer	63	18-08-31

Members of the board	Title	Age	Since
Ian Bothwell DFI	Director of Finance/CFO	63	16-11-03
Steven Glauser BRD	Director/Board Member	76	22-09-22
Gurvinder Pal Singh BRD	Director/Board Member	62	22-08-18
Harry Leider CEO	Chief Executive Officer	66	23-06-05
Leathem Stearn BRD	Director/Board Member	75	22-09-22
George Shapiro CTO	Chief Tech/Sci/R&D Officer	63	18-08-31
Chuck Bretz CHM	Chairman	66	22-09-22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,125,482	3,644,350 ( 59.49 %)	0	59.49 %

Name	Equities	%	Valuation
Ian Bothwell 12.08 %	740,094	12.08 %	1 M $
Bhupendra Kumar Modi 8.163 %	500,000	8.163 %	998 500 $
George Shapiro 6.579 %	403,021	6.579 %	804 833 $
Skycrest Holdings LLC 4.222 %	258,604	4.222 %	516 432 $
Steven Glauser 4.217 %	258,334	4.217 %	515 893 $
Greyt Ventures LLC 4.081 %	250,000	4.081 %	499 250 $
Matthew Sinnreich 2.528 %	154,845	2.528 %	309 225 $
Leathem Stearn 2.041 %	125,000	2.041 %	249 625 $
Harry Leider 0.0857 %	5,247	0.0857 %	10 478 $
Gurvinder Pal Singh 0.000000 %	0	0.000000 %	- $

Name	Equities	%	Valuation
Skycrest Holdings LLC 50.00 %	50	50.00 %	0 $
Greyt Ventures LLC 50.00 %	50	50.00 %	0 $

ZEO ScientifiX, Inc.

3321 College Avenue Suite 246

33314, Davie

http://www.organicell.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Pharmaceuticals Wholesale

	1st Jan change	Capi.
ZEO SCIENTIFIX, INC.	+37.25%	8.97M
MCKESSON CORPORATION	+14.88%	69.29B
SINOPHARM GROUP CO. LTD.	+2.20%	8.36B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+5.20%	8.16B
HUADONG MEDICINE CO., LTD	-20.43%	7.69B
H. LUNDBECK A/S	+0.73%	4.53B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+16.98%	4.47B
EBOS GROUP LIMITED	-2.00%	3.99B
GALENICA AG	-2.89%	3.88B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+21.87%	3.66B

Pharmaceuticals Wholesale